FORMULATION AND DEVELOPMENT OF LORNOXICAM BILAYER TABLETS
Point of present examination work was attempted to figure bilayer tablets of lornoxicam through its joining of oral measurements frame that can release lornoxicam promptly in addition maintained sustained release of lornoxicam for 24 hrs to improve oral bioavailability of lornoxicam. Primary target of this work was plan of bilayer tablets utilizing superdisintegrant Kyron 314 for smart discharge layer Polyox 303 for supporting discharge layer made out of two unique classes of medications by utilizing straight forward simple to-scale-up definition system. The in vitro dissolution study of the prepared bilayer tablets showed a controlled release of active drugs over a period of 24 hours
Key Words:Â Bilayer Tablets, lornoxicam, Superdisintegrant, sustained release
2. Saravanan V., Revathi R., Meera N. Method development and validation for the simultaneous estimation of lycopene and ubidecarenone by RP-HPLC in combined pharmaceutical dosage form. Journal of Drug Delivery and Therapeutics, 2016; 6(5): 46-51.
3. Abebe A, Akseli I, Sprockel O, Kottala N, and Cuitino AM, â€œReview of Bilayer Tablet Technology.â€ International. J. Pharmaceutics, 461, 2014, 549- 558.
4. Dagariya RK, Jat RK, Method development and validation of Irbesartan chlorthalidone and Cilnidipine in their combined tablet dosage form by high performance liquid chromatography, Journal of Drug Delivery and Therapeutics. 2017; 7(4):88-96 DOI: http://dx.doi.org/10.22270/jddt.v7i4.1471
5. Kumar AP, Pramodaganta, Bhoopathi SG and, Kulkarni SV, â€œCurrent Innovation in Layered Tablet Technology: Review.â€ Asian. J. Res pharm. sci. 3, 2013 189-194.
6. Garg A, Gupta MM, Taste masking and formulation development & evaluation of mouth dissolving tablets of levocetrizine dihydrochloride, Journal of Drug Delivery & Therapeutics; 2013; 3(3):123-130
7. Cutolo M, Straub RH, Buttgereit F. Circadian rhythms of nocturnal hormones in rheumatoid arthritis: translation from bench to bedside. Ann Rheum Dis 2008; 67 (7):905-908.
8. Patil S, Gupta V. Design and in vitro evaluation of multiparticulate system for the chronomodulated delivery of lornoxicam. Journal of Drug Delivery and Therapeutics, 2015; 5(3):62-71. doi:10.22270/jddt.v5i3.1148
9. Merck & Co. Inc. The Merck index. 13th ed. Whitehouse Station: Merck & Co. Inc.; 2001.
10. Momin S, Khan S, Ghadage DM, Yadav AV, Wagh A, Formulation and evaluation of bilayer tablets of propranolol hydrochloride, Journal of Drug Delivery and Therapeutics. 2017; 7(2)50-57. DOI: http://dx.doi.org/10.22270/jddt.v7i2.1399
11. Debajyoti Ray, Amresh K Prusty. Designing and invitro studies of gastric floating Tabletss of Tramadol hydrochloride, Int J Appl Pharm. 2010; 2(4):12-16.
12. Patel K, Vyas J, Upadhyay U. Formulation and evaluation of sustained release matrix tablets of nateglinide. Journal of Drug Delivery and Therapeutics, 2015; 5(5):19-25. doi:10.22270/jddt.v5i5.1130
13. Agrawal R, Pharmaceutical processing- a review on wet granulation technology. IJPFR. 2011; (1):65-83
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeÂ The Effect of Open Access).